Pricing Log in Create free account

Maze Therapeutics, Inc. (MAZE) vs Ultragenyx Pharmaceutical Inc. (RARE)

Maze Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Maze Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.5B and $1.5B). Maze Therapeutics, Inc. has the higher net margin (0.00% vs −81.7%) and the lower return on invested capital (−112.4% vs 0.00%). Across the 12 metrics below, Maze Therapeutics, Inc. leads on 7 and Ultragenyx Pharmaceutical Inc. on 5.

Valuation

Metric MAZE RARE Biotechnology median
P/E n/m n/m 8.50
P/S n/m 2.07 9.71
P/B 3.58 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 1.66 9.21
Earnings yield (9.15%) (40.17%) (33.15%)
Free cash flow yield (6.58%) (33.34%) (25.50%)

Profitability

Metric MAZE RARE Biotechnology median
Gross margin — 83.12% 65.16%
Operating margin 0.00% (73.64%) 0.00%
Net margin 0.00% (81.73%) 0.00%
Free cash flow margin 0.00% (68.90%) 0.00%
Return on equity (37.35%) 838.86% (56.36%)
Return on assets (31.99%) (45.60%) (48.04%)
Return on invested capital (112.36%) 0.00% 0.00%

Growth

Metric MAZE RARE Biotechnology median
Revenue growth (TTM) — 17.51% 6.02%
EPS growth (last fiscal year) (344.00%) 7.31% 30.26%
Revenue growth, 5-year CAGR — 19.95% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MAZE RARE Biotechnology median
Debt to equity 0.09 0.00 0.00
Current ratio 18.31 1.73 4.72
Net debt to EBITDA 2.43 1.35 0.96

Dividend

Metric MAZE RARE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MAZE RARE Biotechnology median
Market cap 1.53b 1.50b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack